FI104347B1 - Menetelmä biologisen materiaalin, kuten kudosten ja kehonesteiden syndekaanimäärän määrittämiseksi solujen pahanlaatuisen transformaation todentamiseksi - Google Patents

Menetelmä biologisen materiaalin, kuten kudosten ja kehonesteiden syndekaanimäärän määrittämiseksi solujen pahanlaatuisen transformaation todentamiseksi

Info

Publication number
FI104347B1
FI104347B1 FI933211A FI933211A FI104347B1 FI 104347 B1 FI104347 B1 FI 104347B1 FI 933211 A FI933211 A FI 933211A FI 933211 A FI933211 A FI 933211A FI 104347 B1 FI104347 B1 FI 104347B1
Authority
FI
Finland
Prior art keywords
tissues
body fluids
biological materials
malignant cell
cell transformation
Prior art date
Application number
FI933211A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI104347B (fi
FI933211L (fi
FI933211A0 (fi
Inventor
Markku Tapani Jalkanen
Pirjo Leena Kyllikki Inki
Jarkko Kirjavainen
Sirpa Marianne Leppae
Sakari Markku Mali
Original Assignee
Biotie Therapies Ltd Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27093707&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI104347(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biotie Therapies Ltd Oy filed Critical Biotie Therapies Ltd Oy
Priority to FI933211A priority Critical patent/FI104347B1/fi
Publication of FI933211A0 publication Critical patent/FI933211A0/fi
Publication of FI933211L publication Critical patent/FI933211L/fi
Application granted granted Critical
Publication of FI104347B publication Critical patent/FI104347B/fi
Publication of FI104347B1 publication Critical patent/FI104347B1/fi

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5756—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving tumour-associated glycolinkage [TAG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FI933211A 1991-01-15 1993-07-15 Menetelmä biologisen materiaalin, kuten kudosten ja kehonesteiden syndekaanimäärän määrittämiseksi solujen pahanlaatuisen transformaation todentamiseksi FI104347B1 (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI933211A FI104347B1 (fi) 1991-01-15 1993-07-15 Menetelmä biologisen materiaalin, kuten kudosten ja kehonesteiden syndekaanimäärän määrittämiseksi solujen pahanlaatuisen transformaation todentamiseksi

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US64120991A 1991-01-15 1991-01-15
US64120991 1991-01-15
US72133091A 1991-07-01 1991-07-01
US72133091 1991-07-01
PCT/FI1991/000399 WO1992013274A1 (en) 1991-01-15 1991-12-19 Detection of syndecan content in biological materials such as tissues and body fluids for indications of malignant transformations of cells
FI9100399 1991-12-19
FI933211A FI104347B1 (fi) 1991-01-15 1993-07-15 Menetelmä biologisen materiaalin, kuten kudosten ja kehonesteiden syndekaanimäärän määrittämiseksi solujen pahanlaatuisen transformaation todentamiseksi
FI933211 1993-07-15

Publications (4)

Publication Number Publication Date
FI933211A0 FI933211A0 (fi) 1993-07-15
FI933211L FI933211L (fi) 1993-09-15
FI104347B FI104347B (fi) 1999-12-31
FI104347B1 true FI104347B1 (fi) 1999-12-31

Family

ID=27093707

Family Applications (1)

Application Number Title Priority Date Filing Date
FI933211A FI104347B1 (fi) 1991-01-15 1993-07-15 Menetelmä biologisen materiaalin, kuten kudosten ja kehonesteiden syndekaanimäärän määrittämiseksi solujen pahanlaatuisen transformaation todentamiseksi

Country Status (23)

Country Link
US (1) US5422243A (de)
EP (2) EP0569367B1 (de)
JP (1) JP3103377B2 (de)
KR (1) KR0162670B1 (de)
AT (1) ATE166157T1 (de)
AU (1) AU650936B2 (de)
BG (1) BG61625B1 (de)
CA (1) CA2100077C (de)
CZ (1) CZ282203B6 (de)
DE (1) DE69129417T2 (de)
DK (1) DK0569367T3 (de)
ES (1) ES2116331T3 (de)
FI (1) FI104347B1 (de)
HU (1) HU215778B (de)
IE (2) IE990011A1 (de)
NO (1) NO314604B1 (de)
NZ (1) NZ241273A (de)
PL (1) PL168188B1 (de)
PT (1) PT100008B (de)
RU (1) RU2139540C1 (de)
SK (1) SK281583B6 (de)
WO (1) WO1992013274A1 (de)
ZA (1) ZA92271B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE198271T1 (de) * 1992-12-01 2001-01-15 Biotie Therapies Oy Syndecan-stimulierung der zellulären differenzierung
US5726058A (en) * 1992-12-01 1998-03-10 Jalkanen; Markku Syndecan stimulation of cellular differentiation
US6017727A (en) * 1994-03-07 2000-01-25 Biotie Therapies Ltd. Syndecan enhancer element and syndecan stimulation of cellular differentiation
US5851993A (en) * 1994-06-13 1998-12-22 Biotie Therapies Ltd. Suppression of tumor cell growth by syndecan-1 ectodomain
GB9519490D0 (en) * 1995-09-25 1995-11-29 Melvin William T Use of a cytochrome P450 enzyme in tumour cells as a marker and target
US6385546B1 (en) 1996-11-15 2002-05-07 Rutgers, The University Of New Jersey Stabilizing and destabilizing proteins
NZ502800A (en) * 1997-08-12 2002-10-25 Leadd B The use of apoptin in determining the transforming capability of tumorigenic or tumor promoting agents
CA2346264A1 (en) * 1998-10-16 2000-04-27 Regents Of The University Of California Glypicans for the detection and treatment of human carcinoma
RU2169922C1 (ru) * 1999-02-12 2001-06-27 Трушин Алексей Иванович Способ диагностики областей пролиферации и устройство для его осуществления
US6998232B1 (en) * 1999-09-27 2006-02-14 Quark Biotech, Inc. Methods of diagnosing bladder cancer
WO2001077682A1 (fr) * 2000-04-10 2001-10-18 Institut Bioorganicheskoi Khimii Imeni Akademikov M.M. Shemyakina I Ju. A. Ovchinnikova Rossiisskoi Akademii Nauk Anticorps diriges contre le facteur hldf, procedes de fabrication correspondants, peptides avec des capacites antigeniques et a hydrolyse hk et procede de diagnostic de l'etat anaplasique de cellules humaines
WO2002086084A2 (en) * 2001-04-04 2002-10-31 Quark Biotech, Inc. Sequence characteristics of bladder cancer
RU2279089C1 (ru) * 2004-11-17 2006-06-27 Государственное учреждение Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского (МОНИКИ им. М.Ф. Владимирского) Способ дифференциальной диагностики плоскоклеточного рака кожи и кератоакантомы
KR100694804B1 (ko) * 2005-05-18 2007-03-14 아주대학교산학협력단 작은 헤어핀 ｒｎａ 분자를 포함하는 자궁 내막암 치료또는 예방용 조성물 및 그를 이용한 자궁 내막암 치료 또는예방 방법
US8347890B2 (en) * 2006-06-19 2013-01-08 Insono Therapeutics, Inc. Automated tissue retention system
US20090220588A1 (en) * 2008-02-21 2009-09-03 Massachusetts Institute Of Technology Simultaneous Delivery of Receptors and/or Co-Receptors for Growth Factor Stability and Activity
GB0803272D0 (en) * 2008-02-22 2008-04-02 Smith & Nephew Ultrasound and tissue repair

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2560996B1 (fr) * 1984-03-09 1988-01-15 Commissariat Energie Atomique Procede de dosage immunologique d'antigenes, d'anticorps ou d'haptenes, son utilisation pour le dosage des lipoproteines et de l'a-foetoproteine et trousses de dosage pour la mise en oeuvre de ce procede
DE3511199A1 (de) * 1985-03-28 1986-10-02 Hoechst Ag, 6230 Frankfurt Verfahren zur immunologischen bestimmung von heparansulfat-proteoglykan, verfahren zur herstellung bzw. reinigung von dafuer geeignetem heparansulfat-proteoglykan aus basalmembran-haltigen geweben
US4859581A (en) * 1986-03-10 1989-08-22 Board Of Regents, The University Of Texas System Endoglycosidase assay
US4945086A (en) * 1988-05-03 1990-07-31 The Board Of Trustees Of The Leland Stanford Junior University Smooth muscle cell growth inhibitor
JPH02156898A (ja) * 1988-12-08 1990-06-15 Seikagaku Kogyo Co Ltd 抗低密度型ヘパラン硫酸プロテオグリカンモノクローン抗体、それを産生するハイブリドーマおよびこのモノクローン抗体を用いる低密度型ヘパラン硫酸プロテオグリカンの検出方法
WO1990007712A1 (de) * 1988-12-23 1990-07-12 Bissendorf Peptide Gmbh Antigen, assoziiert mit degenerativen erscheinungen des zentralen nervensystems (zns), dagegen gerichtete antikörper sowie verfahren zur diagnose von dysfunktionen des zns
WO1990012033A1 (en) * 1989-03-29 1990-10-18 The Board Of Trustees Of The Leland Stanford Junior University Construction and use of synthetic constructs encoding syndecan
US5310653A (en) * 1989-10-24 1994-05-10 Board Of Regents, The University Of Texas System Tumor marker protein and antibodies thereto for cancer risk assessment or diagnosis
RU2018835C1 (ru) * 1990-11-11 1994-08-30 Гаркави Любовь Хаимовна Способ прогнозирования течения онкологических заболеваний
WO1993005167A1 (en) * 1991-09-06 1993-03-18 Children's Medical Center Corporation Cell-type specific heparan sulfate proteoglycans and their uses
RU2093832C1 (ru) * 1993-08-31 1997-10-20 Владимир Михайлович Евстропов Способ иммунологической диагностики злокачественного новообразования

Also Published As

Publication number Publication date
CZ282203B6 (cs) 1997-05-14
BG61625B1 (bg) 1998-01-30
HUT67587A (en) 1995-04-28
NO932552D0 (no) 1993-07-14
EP0569367A1 (de) 1993-11-18
ES2116331T3 (es) 1998-07-16
NZ241273A (en) 1993-10-26
PT100008B (pt) 1999-06-30
JP3103377B2 (ja) 2000-10-30
FI104347B (fi) 1999-12-31
ATE166157T1 (de) 1998-05-15
CA2100077A1 (en) 1992-07-16
EP0569367B1 (de) 1998-05-13
IE920107A1 (en) 1992-07-15
SK281583B6 (sk) 2001-05-10
PL168188B1 (pl) 1996-01-31
RU2139540C1 (ru) 1999-10-10
SK73893A3 (en) 1993-11-10
FI933211L (fi) 1993-09-15
EP0816851A2 (de) 1998-01-07
CA2100077C (en) 1999-11-16
FI933211A0 (fi) 1993-07-15
AU9071391A (en) 1992-08-27
DK0569367T3 (da) 1998-10-07
KR0162670B1 (ko) 1999-05-01
HU9302030D0 (en) 1993-11-29
PT100008A (pt) 1993-02-26
US5422243A (en) 1995-06-06
NO932552L (no) 1993-07-14
ZA92271B (en) 1992-10-28
BG97950A (bg) 1995-02-28
AU650936B2 (en) 1994-07-07
DE69129417D1 (de) 1998-06-18
HU215778B (hu) 1999-02-01
WO1992013274A1 (en) 1992-08-06
IE990011A1 (en) 2000-11-01
JPH06504616A (ja) 1994-05-26
EP0816851A3 (de) 2000-08-23
DE69129417T2 (de) 1998-11-05
NO314604B1 (no) 2003-04-14
CZ137293A3 (en) 1994-01-19

Similar Documents

Publication Publication Date Title
FI104347B1 (fi) Menetelmä biologisen materiaalin, kuten kudosten ja kehonesteiden syndekaanimäärän määrittämiseksi solujen pahanlaatuisen transformaation todentamiseksi
Lindberg et al. Mercury-organic matter associations in estuarine sediments and interstitial water
AU1598692A (en) Method of detecting inflammation
CA2156226A1 (en) Biological Fluid Analyzing Device and Method
ATE121196T1 (de) Ermittlungsverfahren und -gerät.
FI940911A0 (fi) Menetelmä ja laite juoksevaa väliainetta sisältävän näytteen mittamista varten
EP0790299A3 (de) Vorrichtung und Verfahren zum Nachweis von Mikroorganismen
WO1997033147A3 (de) Analyseverfahren unter verwendung von porösem silicium zur erfassung einer substanz oder der konzentration einer substanz in lösungen sowie eine analyseeinrichtung für ein solches verfahren
RU93051783A (ru) Способ обнаружения озлокачествления
AU563306B2 (en) A method of detecting or determining histamine in histamine containing materials, particularly body fluids and an analytical means for use in such method
Holt et al. A high performance liquid chromatography system for the simultaneous assay of some antibiotics commonly found in combination in clinical samples
FI861205A0 (fi) Foerfarande foer koncentration och detektering av biomolekyler och celler och medel foer detta.
SE9401646L (sv) Anordning för bestämning av blodets sänkningsreaktion
Karklina et al. Dioxyacetone measurement in the culture liquids of Acetobacter suboxydans.
DK0431567T3 (da) Fremgangsmåde til påvisning af et småcellet bronchial-carcinom
Daly et al. Early experience with a highly sensitive bioassay for ACTH
Grizzle Special Symposium Biomarkers—The New Frontier in the Pathology of Invasive and Preinvasive Neoplasias
Koen et al. Methods of Determining Arsenic and Its Compounds in Air, Water, Biomaterials, and Other Environmental Media
Huanqiang Turbidimetry for measurement of radon concentration
BRUEGGEMAN Viscoelastic properties of dilute polymer solutions and polymer-loaded oils[Ph. D. Thesis]
SE9304370D0 (sv) Metod och anordning för mätning av rengörings kapaciteten hos ett rengöringsbad
SE9302723D0 (sv) Förbättrad metod för detektion av ämnen i en vätska

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: OY BIOTIE THERAPIES LTD.